Pharsight

Odomzo is owned by Sun Pharm.

Odomzo contains Sonidegib Phosphate.

Odomzo has a total of 3 drug patents out of which 0 drug patents have expired.

Odomzo was authorised for market use on 24 July, 2015.

Odomzo is available in capsule;oral dosage forms.

Odomzo can be used as treatment of basal cell carcinoma.

The generics of Odomzo are possible to be released after 30 March, 2036.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178563	SUN PHARM	Compounds and compositions as hedgehog pathway modulators	Jul, 2029 (6 years from now)
US8063043	SUN PHARM	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide	Sep, 2029 (6 years from now)
US10266523	SUN PHARM	Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof	Mar, 2036 (13 years from now)